DR5 Antibody Cat. No.: 2019

Figure 1 Western Blot Validation in Human Cell Lines
Loading: 15 μg of lysates per lane. Antibodies: DR5 2019, (0.5 μ g/mL), 1h incubation at RT in 5% NFDM/TBST. Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution. See high quality image.

Figure 2 Western Blot Validation in Mouse Cell Lines
Loading: 15 μg of lysates per lane. Antibodies: DR5 2019, (1 μg/mL), 1h incubation at RT in 5% NFDM/TBST. Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution. See high quality image.

Figure 3 Immunofluorescence Validation of DR5 in Mouse Kidney tissue
Immunofluorescent analysis of 4% paraformaldehyde-fixed mouse kidney tissue labeling DR5 with 2019 at 20 μg/mL, followed by goat anti-rabbit IgG secondary antibody at 1/500 dilution (red). See high quality image.

Figure 4 Immunocytochemistry Validation of DR5 in HeLa Cells
Immunocytochemical analysis of HeLa cells using anti-DR5 antibody (2019) at 5 μg/ml. Cells was fixed with formaldehyde and blocked with 10% serum for 1 h at RT; antigen retrieval was by heat mediation with a citrate buffer (pH6). Samples were incubated with primary antibody overnight at 4˚C. A goat anti-rabbit IgG H&L (HRP) at 1/250 was used as secondary. Counter stained with Hematoxylin. See high quality image.

Figure 5 Immunofluorescence Validation of DR5 in HeLa Cells
Immunofluorescent analysis of 4% paraformaldehyde-fixed HeLa cells labeling DR5 with 2019 at 20 μg/mL, followed by goat anti-rabbit IgG secondary antibody at 1/500 dilution (green). See high quality image.

Figure 6 Immunohistochemistry Validation of DR5 in Mouse kidney tissue
Immunohistochemical analysis of paraffin-embedded mouse kidney tissue using anti-DR5 antibody (2019) at 5μg/ml. Tissue was fixed with formaldehyde and blocked with 10% serum for 1 h at RT; antigen retrieval was by heat mediation with a citrate buffer (pH6). Samples were incubated with primary antibody overnight at 4˚C. A goat anti-rabbit IgG H&L (HRP) at 1/250 was used as secondary. Counter stained with Hematoxylin. See high quality image.

Figure 7 KO Validation of DR5 in HCT116 Cells (Han et al., 2015)
Anti-cancer drug, Carfilzomib (CFZ), induced up-regulation of DR5 and the expression of DR5 was not detected in DR5-KO HCT 116 cell line with anti-DR5 antibodies (2019). See high quality image.

Figure 8 KD Validation of DR5 in MB231 Cells (Rahman et al., 2009)
Western blot analysis with anti-DR5 antibodies was performed for DR5 in MB231 cells transfected with control siRNA or DR5 siRNA. DR5 expression was disrupted after DR5 siRNA knockdown. See high quality image.

Figure 9 Immunohistochemistry Validation of BIM in Human Colon Tumors (Devetzi et al., 2016)
Protein analysis for DR5 by immunohistochemistry with anti-DR5 antibodies in human colon tumors. Strong immunoreactivity is shown for DR5 in T167 patient with colorectal cancer. See high quality image.

Figure 10 Regulated Expression Validation of DR5 in Thyroid Epithelial Cells (Bretz et al., 2002)
Immunostaining with anti-DR5 antibodies shows high levels of DR5 expression in untreated cells and cells treated with each of the three cytokines alone or TNFalpha combined with IL-1b. In contrast, treatment with both IFNg and TNFalpha or all three cytokines greatly reduces DR5 staining. The reduction in staining appears most significant in cytoplasmic regions while some staining is maintained in or around the nucleus. See high quality image.

Figure 11 Immunofluorescence Validation of DR5 in Rat Brain Tissue with Tumors (Candolfi et al., 2009)
Rats were implanted in the striatum with CNS-1 tumors and 9 days later brains were processed for immunocytochemistry. Confocal microphotographs show detection of therapeutic targets (green) using specific antibodies against the death receptors TNFR1 and TRAILR2. Tumor cells were labeled with anti-vimentin antibodies (red), neurons were stained with anti-NeuN (red) and astrocytes with anti-GFAP antibodies (red). Nuclei were stained with DAPI (blue). T: tumor area. N: necrotic patch. See high quality image.